Serum neutrophil gelatinase-associated lipocalin at inception of renal replacement therapy predicts survival in critically ill patients with acute kidney injury by Kümpers, Philipp et al.
RESEARCH Open Access
Serum neutrophil gelatinase-associated lipocalin
at inception of renal replacement therapy
predicts survival in critically ill patients with acute
kidney injury
Philipp Kümpers
1,2*†, Carsten Hafer
1†, Alexander Lukasz
1, Ralf Lichtinghagen
3, Korbinian Brand
3, Danilo Fliser
4,
Robert Faulhaber-Walter
1†, Jan T Kielstein
1†
Abstract
Introduction: Neutrophil gelatinase-associated lipocalin (NGAL) is a promising novel biomarker that correlates with
the severity and outcome of acute kidney injury (AKI). However, its prognostic utility during the late course of AKI,
especially in patients that require renal replacement therapy (RRT) remains unknown. The aim of this study was to
evaluate the predictive value of serum NGAL in patients with established AKI at inception of RRT in the intensive
care unit (ICU).
Methods: Serum NGAL (ELISA methodology) was measured in 109 critically ill patients with AKI at inception of RRT
in 7 ICUs of a tertiary care university hospital. The primary outcome studied was 28-day mortality. Secondary
outcome measures were ICU length of stay, ventilator-free days, and renal recovery at day 28.
Results: There was a significant difference in serum NGAL between healthy subjects (median [interquartile range]
39.0 [37.5-42.75] ng/mL), critically ill patients with systemic inflammatory response syndrome (SIRS) (297 [184-490]
ng/mL), and critically ill patients with sepsis (708 [365-1301] ng/mL; P < 0.0001), respectively. Multiple linear
regression showed that NGAL levels were independently related to the severity of AKI and the extent of systemic
inflammation. NGAL levels were higher in non-survivors (430 [303-942] ng/mL) compared to survivors (298 [159-
506] ng/mL; P = 0.004). Consistently, Cox proportional hazards regression analysis identified NGAL as a strong
independent predictor for 28-day survival (hazard ratio 1.6 (95% confidence interval [CI] 1.15 - 2.23), P = 0.005).
Conclusions: This is the first prospective evaluation of serum NGAL as an outcome-specific biomarker in critically ill
patients at initiation of RRT. The results from this study indicate that serum NGAL is as an independent predictor of
28-day mortality in ICU patients with dialysis-dependent AKI.
Introduction
Acute kidney injury (AKI) is a frequent complication in
critically ill patients and is associated with an excess
mortality [1-4]. AKI requiring renal replacement therapy
(RRT) affects approximately 6% of critically ill patients
and results in a hospital mortality of 45 to 60% [4-6].
Outcome prediction in this selected high-risk collective
is challenging due to the lack of appropriate biomarkers
and the limited value of severity-of-illness scoring sys-
tems [7-10]. Thus, the identification of outcome-specific
biomarkers in this patient population is a major goal in
critical care nephrology.
In experimental and clinical studies, neutrophil gelati-
nase-associated lipocalin (NGAL) is one of the most fre-
quently investigated and most promising biomarkers for
the early diagnosis of AKI. In fact, NGAL (also known
as lipocalin 2 or lcn2) was found to be an excellent bio-
marker for the early detection of AKI in the emergency
department [11], after exposure to radio-contrast media
[12-14], and following cardiac surgery [15-19]. There is
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AKI per se but also a predictor of AKI severity and
AKI-related outcomes such as requirement of RRT,
length of hospital stay (LOS), and mortality [15,20].
However, despite its well-defined role in the early
detection of AKI, little is known about the diagnostic
and prognostic utility of NGAL during the clinical
course in patients with established AKI. Therefore, we
aimed to investigate the outcome-specific value of
NGAL, measured at initiation of RRT in critically
patients with severe AKI.
Materials and methods
Patients and study design
The present investigation is a sub-study from the Hann-
over Dialysis Outcome Trial (HANDOUT), a single-cen-
ter randomized controlled trial comparing standard and
intensified extended dialysis therapy in patients with
AKI at seven intensive care units (ICUs) of our tertiary
care center at the Hannover Medical School between
2003 and 2006. The protocol and main results of the
HANDOUT trial (Clinical Trial ID: NCT00529139) have
been published recently [21].
Serum samples for quantification of NGAL were avail-
able from 109 patients (Table 1). All patients were trea-
ted with extended dialysis, using the GENIUS™ dialysis
system (Fresenius Medical Care, Bad Homburg, Ger-
many) [22] with high-flux polysulphone dialyzers (F60S,
1.3 m
2, Fresenius Medical Care, Bad Homburg,
Germany).
Inclusion criteria were AKI with RRT dependence
indicated by a loss of kidney function of more than 30%
calculated estimated glomerular fraction rate (eGFR)
with either the Modification of Diet in Renal Disease
(MDRD), Cockroft-Gault equation or cystatin C GFR
within 48 hours prior to inclusion and oliguria/anuria
(less than 30 mL/h for more than six hours prior to
inclusion or hyperkalaemia more than 6.5 mmol/L) or
severe acidosis with pH below 7.15. Urine output was
determined under optimized conditions (corrected
volume status, adequate titration of vasopressors, and
after an unavailing trial of loop diuretics). Exclusion
Table 1 Baseline characteristics at initiation of RRT
Variable Total non-SIRS/sepsis SIRS Sepsis P value
Number of patients (n; %) 109 (100) 25 (22.9) 53 (48.6) 31 (28.4)
Age (years, median (IQR)) 51 (40-61) 56 (47-68) 51 (39-60) 48 (37-61) 0.086
Female sex (n;%) 42 (38.5) 5 (20.0) 25 (47.2) 12 (38.7) 0.071
LOS before start of RRT (median (IQR)) 2 (1-5) 3 (2-5) 2 (1-7) 2 (1-5) 0.426
APACHE II score (median (IQR)) 34 (26-36) 34 (27-36) 30 (24-35) 35 (29-40) 0.028
SOFA score (median (IQR)) 16 (13-18) 15 (13-17) 14 (12-17) 17 (16-19) 0.011
Cardiovascular variable 4 (1-4) 3 (1-4) 3 (1-4) 4 (3-4) 0.008
Respiratory variable 2 (2-3) 2 (2-3) 2 (1-3) 3 (2-4) 0.005
Coagulation variable 1 (1-3) 1 (1-3) 1 (1-3) 3 (1-3) 0.567
Liver variable 1 (1-2) 1 (1-2) 2 (1-2) 1 (1-2) 0.858
Renal variable 3 (2-4) 3 (2-4) 3 (2-4) 3 (2-4) 0.517
CNS variable 4 (3-4) 4 (4-4) 4 (2-4) 4 (4-4) 0.009
Indication for RRT
CCR/eGFR loss >30% (n;%) 100 (91.7) 23 (92.0) 49 (92.5) 28 (90.3) 0.942
Oliguria (n;%) 78 (71.6) 18 (72.0) 36 (37.9) 24 (77.4) 0.647
Severe acidosis (n;%) 10 (9.2) 0 (0) 5 (9.4) 5 (16.5) 0.115
Hyperkalemia (n;%) 6 (5.5) 0 (0) 3 (5.7) 3 (9.7) 0.287
RIFLE class 0.947
Risk (n;%) 9 (8.3) 2 (8.0) 5 (9.4) 2 (6.5)
Injury (n;%) 13 (11.9) 2 (8.0) 7 (13.2) 4 (12.9)
Failure (n;%) 87 (79.8) 21 (84.0) 41 (77.4) 25 (80.6)
Laboratory data (median (IQR))
CRP (mg/L) 138 (59-204) 113 (60-155) 67 (36-176) 202 (138-303 <0.001
Creatinine (μmol/L) 236 (185-313) 277 (189-350) 250 (191-348) 203 (152-257) 0.475
Cystatin C (mg/L) 1.82 (1.37-2.68) 1.81 (1.47-2.4) 1.82 (1.41-2.93) 1.84 (1.27-2.47) 0.676
NGAL (ng/mL) 364 (196-582) 297 (184-490) 315 (161-455) 708 (365-1301) 0.001
APACHE II score = Acute Physiology And Chronic Health Evaluation score; CCR = creatinine clearance; CNS = central nervous system; CRP = C reactive protein;
eGFR = estimated glomerular filtration rate; IQR = interquartile range; LOS = length of stay in the intensive care unit; NGAL = neutrophil gelatinase-associated
lipocalin; RIFLE = a newly developed international consensus classification for acute kidney injury, that defines three grades of severity - risk (class R), injury (class
I) and failure (class F); RRT = renal replacement therapy; SOFA = Sequential Organ Failure Assessment score; SIRS = systemic inflammatory response syndrome.
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defined as eGFR less than 50 mL/min or plasma creati-
nine concentration above 1.7 mg/dL (above 150 μmol/L)
more than 10 days prior to initiation of the first RRT.
Enrollment was performed in a randomized consecu-
tive fashion after obtaining written informed consent
from the patients or their legal representatives. If the
patient was recovering and able to communicate, he or
she was informed of the study purpose and consent was
required to further maintain status as a study partici-
pant. The study was performed in accordance with the
declaration of Helsinki and approved by the institutional
review board.
Routine chemistry tests and physiological parameters,
including Sequential Organ Failure Assessment (SOFA)
score [23] and Acute Physiology and Chronic Health
Evaluation II (APACHE II) score [24] were obtained for
each patient immediately before initiation of RRT. The
presence of sepsis was defined according to the SCCM/
ESICM/ACCP/ATS/SIS International Sepsis Definitions
(Two or more of the following findings: body tempera-
ture < 36°C or > 38°C, heart rate > 100 beats per min-
ute, respiratory rate > 20 breaths per minute, or white
blood cell count < 4,000 cells/mm
3 or > 12,000 cells/
mm
3 in addition to suspected or proven infection) [25].
AKI was classified post-hoc by means of the RIFLE (risk
of renal failure, injury to kidney, failure of kidney func-
tion, loss of kidney function and end-stage renal failure)
criteria at initiation of RRT [26].
Sampling and quantification of NGAL
Serum cystatin C and serum C reactive protein (CRP)
levels were determined by routine methods in the
department of clinical chemistry at Hannover Medical
School. Serum samples for quantification of NGAL were
obtained for each patient immediately before initiation
of RRT, immediately centrifuged at 3000 g for 10 min-
utes, divided into aliquots and stored at -80°C. NGAL
was quantified in a blinded fashion by ELISA (NGAL
Rapid ELISA Kit CE IVD [Cat.No. KIT 037], BioPorto,
Gentofte, Denmark) according to the manufacturer’s
instructions [27]. The serum concentration (median
(interquartile range (IQR))) of NGAL in 10 apparently
healthy volunteers was 39 (37.5 to 42.8) ng/mL.
Outcome definitions
Survival after 28 days was calculated from the day of
first dialysis to death from any cause. Patients who sur-
vived to day 28 were censored at day 28. Ventilator-free
days (VFDs) were defined as the number of days
between successful weaning from mechanical ventilation
and day 28 after study enrollment. VFDs were 0 if the
patient died before day 28 or required mechanical venti-
lation for 28 days or more. ICU-free days were defined
as the number of days between successful transfer to a
normal ward and day 28 after study enrollment. ICU-
free days were 0 if the patient died before day 28 or
stayed in the ICU for 28 days or more. Renal recovery
was defined as no need for RRT at day 28 after study
enrollment.
Statistical analysis
Continuous variables are expressed as medians with
corresponding 25
th and 75
th percentiles (IQR) and
were compared using the Mann-Whitney rank sum test
or the Kruskal Wallis one-way analysis of variance
(ANOVA). Categorical variables were compared using
the chi-squared test. Correlations between variables
were assessed by the Spearman rank correlation coeffi-
cient. To identify predictors of mortality, Cox’s propor-
tional hazards regression analysis was performed using
backward elimination (Wald’s test). Simple and multi-
ple linear regression analysis was performed to identify
which variables best predict NGAL. Similarly, linear
regression and binary logistic regression models were
used to identify predictors of VFDs, ICU-free days, and
renal recovery, respectively. To ful?ll the assumptions
needed for the analysis, logarithmic transformation of
SOFA score, single SOFA score items, APACHE II
score, CRP, and NGAL was performed. The distribu-
tion of the time-to-event variables were estimated
using the Kaplan-Meier method with log-rank testing.
Receiver operator characteristic (ROC) curves were
used to detect optimal cut-off values for NGAL. Con-
tingency table-derived data and likelihood ratios were
calculated using the StatPages website [28]. All tests
were two-sided and significance was accepted at P <
0.05. Data analysis was performed using SPSS (SPSS
Inc, Chicago, IL, USA). Figures were prepared using
the GraphPad Prism (GraphPad Prism Software Inc,
San Diego, CA, USA).
Results
Patient characteristics
Patients were grouped as non-systemic inflammatory
response syndrome (SIRS)/sepsis, SIRS, and sepsis
according to the International Sepsis Definitions [25].
Patient groups were comparable with respect to baseline
demographics, LOS in the ICU before start of RRT,
indications for RRT, and the proportion of RIFLE cate-
gories (Table 1). Patients with sepsis had moderately
higher SOFA scores that resulted from more severe car-
diovascular and respiratory impairment compared with
patients with either non-SIRS/sepsis, or SIRS, respec-
tively. Consistently, septic patients had poorer 28-day
survival (Table 2). However, secondary outcomes, such
as VFDs, ICU-free days, or renal recovery, were not dif-
ferent between the groups (Table 2).
Kümpers et al. Critical Care 2010, 14:R9
http://ccforum.com/content/14/1/R9
Page 3 of 9Predictors of serum NGAL levels at baseline
Critically ill patients had significantly higher serum
NGAL levels at initiation of RRT compared with healthy
controls (364 (196 to 582) ng/mL vs. 39.0 (37.5 to 42.75)
ng/mL; P < 0.0001). To identify which mediator or index
is best related to NGAL, we initially carried out a linear
regression analysis for all baseline variables included in
Table 1. All variables found to be statistically significant
at a 10% level in the simple model were then included in
a multiple linear regression model using backward elimi-
nation. Using NGAL as the dependent variable, the pre-
sence of sepsis, the renal variables from the SOFA score,
CRP, and serum cystatin C were independently related to
NGAL levels at initiation of RRT (Table 3). As expected,
serum NGAL concentrations were significantly higher in
patients with sepsis compared with patients without sep-
sis (834 ± 118 ng/mL (mean ± standard error of the
mean (SEM)) vs. 425 ± 57 ng/mL; P <0 . 0 0 1 ;F i g u r e1 ) .
No difference was found between patients with SIRS and
non-SIRS/sepsis patients (Table 1). Furthermore, serum
NGAL steadily increased across groups when stratified
by the renal variable from the SOFA score (1 point: 220
± 42, 2 points: 430 ± 63, 3 points: 489 ± 89, 4 points: 700
±1 1 4 ;P = 0.03 by non-parametric ANOVA; Figure 1).
The relation of NGAL with these variables was further
illustrated by linear correlation analysis, showing that
NGAL levels correlated with CRP (r = 0.51; P < 0.0001),
and cystatin C (r = 0.39; P < 0.0001) levels, respectively
(Figure 1).
NGAL levels during follow-up
Serum samples obtained at day 14 were available from 61
patients. After initiation of RRT, NGAL levels declined
significantly until day 14 (364 (196 to 582) ng/mL vs. 206
(93 to 349) ng/mL; P < 0.0001). However, median NGAL
levels were not different between survivors (176 (89 to
338) ng/mL, n = 49) and non-survivors (281 (138 to 726)
ng/mL, n = 12; P = 0.114), respectively.
Predictors of 28-day mortality at inception of RRT
NGAL levels were higher in non-survivors (430 (303 to
942) ng/mL) compared with survivors (298 (159 to 506)
ng/mL; P = 0.004). To test whether pre-RRT levels of
NGAL predict 28-day mortality, we initially performed
univariate Cox proportional hazards analyses, incorpor-
ating multiple demographic, clinical and laboratory vari-
ables at start of RRT (Table 4). All variables found to be
statistically significant at a 10% level in the univariate
analysis (sepsis, APACHE II score, SOFA score, CRP,
and NGAL) were subjected to multivariate Cox regres-
sion analysis. As a result, the SOFA score (P =0 . 0 0 4 ) ,
and serum NGAL (P =0 . 0 0 5 )w e r ei d e n t i f i e da si n d e -
pendent predictors of 28-day mortality. Essentially, the
same results were obtained in an adjusted model incor-
porating treatment intensity of RRT (standard vs. inten-
sified extended dialysis in the original HANDOUT trial).
When visualized by Kaplan-Meier curves, mortality
was no different between NGAL quartile (Q) 1 and Q2,
but steadily increased among Q3 and Q4 (Log-rank
(Mantel-Cox) P = 0.01; Log-rank test for trend P =
0.003; Figure 2a). Similarly, 28-day mortality was low in
the SOFA Q1, intermediate in Q2 and Q3, and high in
SOFA Q4, respectively (Log-rank (Mantel-Cox) P =
0.01; Log-rank test for trend P = 0.002; Figure 2b).
Table 2 Outcomes at day 28 after initiation of RRT
Variable Total non-SIRS/sepsis SIRS Sepsis P value
Mortality (n;%) 41 (37.6) 6 (24.9) 15 (28.3) 20 (64.5) 0.001
VFDs (mean ± SD) 7.4 ± 10.3 5.5 ± 9.5 8.3 ± 10.7 7.2 ± 10.1 0.580
ICU-free days
† (mean ± SD) 5.2 ± 8.4 4.6 ± 8.3 5.4 ± 8.4 5.4 ± 8.8 0.738
Renal recovery
‡ (n;%) 45 (66.2) 13 (68.4) 26 (68.4) 6 (54.5) 0.673
ICU = intensive care unit; SD = standard deviation; SIRS = systemic inflammatory response syndrome; VFDs = ventilator-free days (defined as the numbero fd a y s
between successful weaning from mechanical ventilation and day 28 after study enrollment).
† ICU-free days were defined as the number of days between successful transfer to a normal ward and day 28 after study enrollment; ‡ Renal recovery was
defined as no need for RRT at day 28 after study enrollment.
Table 3 Simple and multiple linear regression analysis
with neutrophil gelatinase-associated lipocalin as
dependent variable
Simple model Multiple model
Variable BP value b P value
Sepsis (yes/no) 0.37 <0.0001 0.33 < 0.001
RIFLE category failure* 0.23 0.018 0.04 0.693
ln SOFA - total 0.16 0.098 0.03 0.738
ln SOFA - respiratory variable 0.17 0.075 0.13 0.140
ln SOFA - renal variable 0.22 0.020 0.23 0.007
ln CRP 0.40 <0.0001 0.21 0.031
ln cystatin C 0.34 <0.0001 0.26 0.005
Multiple linear regression analysis using neutrophil gelatinase-associated
lipocalin as the dependent variable. Variables found to be statistical significant
at a P value less than 0.1 in the simple model were included into the multiple
linear regression analysis using stepwise backward elimination. Variables that
were not normally distributed were log transformed. (b denotes standardized
regression coefficient); A two-sided P value of less than 0.05 was considered
statistically significant in the multiple model. * b for categorical variables is
only displayed in case of multivariate significance.
CRP = C reactive protein; RIFLE = a newly developed international consensus
classification for acute kidney injury, that defines three grades of severity -
risk (class R), injury (class I) and failure (class F); SOFA = Sequential Organ
Failure Assessment score.
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Page 4 of 9Figure 1 Correlation of NGAL serum levels. (a and c). Correlation of NGAL serum levels with sepsis and acute kidney injury (AKI). Bar charts
(mean ± standard error of the mean) showing serum neutrophil gelatinase-associated lipocalin (NGAL) levels of critically ill patients with AKI at
inception of renal replacement therapy (RRT) stratified by (a) the presence (n = 31) or absence (n = 78) of sepsis as according to the SCCM/
ESICM/ACCP/ATS/SIS International Sepsis Definitions [25], or (c) stratified by the renal variable from the Sequential Organ Failure Assessment
(SOFA) score (1 point (n = 9), 2 points (n = 27), 3 points (n = 28), 4 points (n = 45)). (b and d) Scatter plot showing the correlation of serum
NGAL concentrations with (c) C reactive protein (CRP) levels, and (d) serum cystatin C levels in critically ill patients at initiation of RRT (n = 109).
Table 4 Predictors of 28-day mortality using Cox proportional hazards regression analysis
Univariate Multivariate
Variables HR (95% CI) P value HR (95% CI) P value
Age (per 10 years) 0.97 (0.79-1.20) 0.791
Sex (female) 0.76 (0.40-1.45) 0.401
SIRS
† 1.22 (0.48-3.16) 0.675
Sepsis
† 3.54 (1.42-8.82) 0.007
RIFLE category* – 0.381
ln SOFA - renal variable (per 1 SD ↑) 1.05 (0.66-1.67) 0.846
LOS before start of RRT (per day) 1.00 (0.96-1.04) 0.889
ln APACHE II score (per 1 SD ↑) 1.72 (1.15-2.56) 0.008
ln total SOFA score (per 1 SD ↑) 1.79 (1.28-2.50) <0.001 1.62 (1.17-2.25) 0.004
ln CRP (per 1 SD ↑) 1.71 (1.13-2.58) 0.012
ln cystatin C (per 1 SD ↑) 1.07 (0.77-1.50) 0.679
ln NGAL (per 1 SD ↑) 1.79 (1.28-2.51) <0.001 1.60 (1.15-2.23) 0.005
Estimated hazard ratios (HR), 95% confidence intervals (CI), and P values were calculated by Cox regression analyses (backward elimination). Variables found to
be statistical significant at a P value of less than 0.1 in the univariate model were included into the multivariate model using stepwise backward elimination. A
two-sided P value of less than 0.05 was considered statistically significant in the multivariate model. Variables that were not normally distributed were log
transformed; hazard ratios refer to 1 standard deviation (SD) in the log scale in these variables. † For SIRS and sepsis, the non-SIRS/sepsis group was set as the
reference group. *HR (95% CI) for categorical variables is only displayed in case of multivariate significance.
APACHE II score = Acute Physiology And Chronic Health Evaluation score; CRP = C reactive protein; LOS = length of stay in the intensive care unit; NGAL =
neutrophil gelatinase-associated lipocalin; RIFLE = a newly developed international consensus classification for acute kidney injury, that defines three grades of
severity - risk (class R), injury (class I) and failure (class F); RRT = renal replacement therapy; SOFA = Sequential Organ Failure Assessment score; SIRS = systemic
inflammatory response syndrome.
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at initiation of RRT
To assess the utility of NGAL measurements at vary-
ing cut-off values to predict mortality, a conventional
ROC curve was generated and the area under the
curve (AUC) calculated (Figure 3). Table 5 lists the
derived sensitivities, specificities, and predictive values
at different cut-off concentrations (according to
NGAL Qs). For serum NGAL at initiation of RRT,
sensitivity and specificity were optimal at the 360 ng/
mL cut-off, with an AUC of 0.74 (95% confidence
interval (CI) 0.64 to 0.84) for the prediction of death
before day 14 (Figure 2).
Secondary outcome measures
Renal recovery (defined as no need for dialysis in survi-
vors at the end of the study period) was not associated
with serum NGAL levels as determined by binary
logistic regression analysis (P =0 . 8 4 ) .T h es a m ew a s
true for VFDs (P = 0.75) and for ICU-free days (P =
0.574), as shown by linear regression analysis,
respectively.
Discussion
This is the first study investigating the predictive value
of NGAL for the outcome of critically ill patients with
established AKI at initiation of RRT. Elevated serum
NGAL is independently related to the severity of AKI
(cystatin C and renal SOFA), but also to the presence of
sepsis and the extent of systemic inflammation (CRP).
Serum NGAL was higher in critically ill patients who
died compared with patients who survived during the
study period. Consistently, Cox proportional hazards
regression analysis identified NGAL as an independent
predictor for 28-day survival in our cohort.
Gene expression studies in AKI have demonstrated
that NGAL is highly up-regulated in the thick ascending
limb of Henle’s loop and the collecting ducts [29]. The
resultant synthesis of NGAL protein in the distal
Figure 2 Survival to day 28 according to serum NGAL.K a p l a n -
Meier curves of 28-day survival stratified to (a) neutrophil
gelatinase-associated lipocalin (NGAL) quartiles (Q) (Log-rank
(Mantel-Cox) P = 0.01; Log-rank test for trend P = 0.003), and (b)
Sequential Organ Failure Assessment (SOFA) quartiles (total SOFA),
respectively (Log-rank (Mantel-Cox) P = 0.01; Log-rank test for trend
P = 0.002) at inception of renal replacement therapy in critically ill
patients with acute kidney injury (n = 109).
Figure 3 Serum NGAL test characteristics at various cut-off
values at initiation of RRT. Receiver-operator characteristic (ROC)
curve showing the prognostic sensitivity and specificity of serum
neutrophil gelatinase-associated lipocalin (NGAL) at initiation of
renal replacement therapy (RRT) with regard to 14-day mortality
(area under the curve (AUC) 0.74 (95% confidence interval (CI) 0.64
to 0.84) P < 0.0002). Cuboids indicate the cut-off values between
NGAL quartiles (see also Figure 2 and Table 5).
Table 5 Serum NGAL test characteristics at various cut-off
values at initiation of renal replacement therapy
NGAL cut-off OR Sensitivity
(%)
Specificity
(%)
NPV
(%)
PPV
(%)
≥ 580 ng/mL 4.79 50.0 82.7 82.7 50.0
≥ 360 ng/mL 6.69 82.1 59.2 90.6 41.1
≥ 190 ng/mL 3.31 89.3 28,4 88.5 30.1
NGAL = neutrophil gelatinase-associated lipocalin; NPV = negative predictive
value; OR = odds ratio; PPV = positive predictive value.
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prise the major fraction of urinary NGAL [29,30]. It is
assumed that urinary NGAL is probably more reflective
of local renal injury [29,31], because systemic NGAL in
serum or plasma may, at least in part, be derived from
stressed immune cells and injured epithelial cells of the
lungs and the gastrointestinal tract [32,33]. Wheeler and
colleagues demonstrated that serum NGAL concentra-
tions were increased at 24 and 72 hours after ICU
admission in children who developed AKI compared
with children who did not develop AKI [20]. Of note, in
the same cohort, serum NGAL was significantly
increased in critically ill children with sepsis compared
with critically ill children without sepsis.
In the present study, both, the presence of sepsis as
well as the severity of AKI were independently asso-
ciated with increased serum NGAL concentrations in a
multiple linear regression analysis model. Thus we
assume that plasma NGAL not only depicts AKI, but
also reflects the severity of systemic inflammation. In
line with this interpretation, increased NGAL concentra-
tions have been found in the blood of patients with
acute bacterial infections and during experimental
human endotoxemia [34,35]. Unfortunately, urinary
NGAL could not be determined because most of the
patients presented with oliguria/anuria at baseline. Thus,
we cannot provide any comparison between the local
and systemic NGAL pool in the current study. However,
to date, there is no conclusive evidence for urine NGAL
being superior to plasma NGAL [17,18,20,36,37].
Recent studies have demonstrated the utility of early
NGAL measurements for predicting clinical outcomes
of AKI. In adults and children undergoing cardiac sur-
gery, plasma NGAL levels strongly correlated with dura-
tion and severity of AKI, time on mechanical
ventilation, LOS, and mortality [17,36,37]. However, the
predictive utility of NGAL throughout the course of cri-
tical illness in patients with already established AKI is
poorly characterized and has not been tested specifically
at the initiation of RRT. In the current study, serum
NGAL was identified as an independent predictor of 28-
day mortality in the multivariate Cox model. In addition
to serum NGAL, only the (total) SOFA score remained
significant at the multivariate level. A ROC analysis sug-
gested that a serum NGAL cutoff value of 360 ng/mL at
initiation of RRT is highly sensitive to discriminate
between survivors and non-survivors. Given a rather
poor positive predictive value of 41%, a serum NGAL
level of 360 ng/mL or greater probably does not serve
as a robust biomarker for predicting mortality in this
cohort of patients. However, NGAL levels of less than
360 ng/mL may have the potential to predict survival
with a negative predictive value of 90%. If validated in a
larger cohort, our observations suggest a pivotal role for
serum NGAL as an outcome-specific marker in critically
ill patients with multiple organ dysfunction syndrome.
This study has important limitations. First, it is a single-
center cohort study of adult patients without chronic kid-
ney disease. Our results, although of clear statistical signif-
icance, will certainly need to be validated in a larger trial,
including patients with pre-existing chronic kidney disease
and comorbid conditions that normally accumulate with
impaired renal function. Moreover, the original study was
performed between 2003 and 2006. It has been indicated
that long-term storage might destabilize NGAL [38].
Thus, extrapolating our result to other ICU populations
requires caution. Second, NGAL did not predict secondary
outcomes, such as renal recovery, VFDs, or ICU-free days.
This discrepancy may have resulted from the relatively
small number of VFDs and ICU-free days. Unfortunately,
the follow-up was only 28 days in the original HANDOUT
trial. Moreover, weaning from mechanical ventilation was
not guided by standardized protocol. The same was true
for discharge from ICU. Third, the NGAL cutoff in the
current study was somewhat higher than in most of the
aforementioned AKI studies. However, this is not surpris-
ing because most of our patients already presented with
severe AKI (RIFLE category failure). Finally, NGAL was
not different between survivors and non-survivors at day
14. However, as a 25 kDa protein NGAL is most likely to
be cleared by dialysis. Thus, the quantification of NGAL
after the start of RRT will probably yield invalid results.
Conclusions
Outcome prediction in dialysis-dependent ICU patients
is hampered by the limited value of severity-of-illness
scoring systems [7-10]. Thus, the identification of out-
come-specific biomarkers in this patient population is a
major goal in critical care nephrology. The results from
this study indicate that serum NGAL, measured at
initiation of RRT, is as an independent predictor of 28-
day mortality in ICU patients with AKI. Given the lack
of appropriate biomarkers in these patients, serum
NGAL may serve as a novel outcome-specific marker in
intensive care medicine and critical care nephrology.
Key messages
￿ This is the first prospective evaluation of serum NGAL
as an outcome-specific biomarker in critically ill patients
at initiation of RRT.
￿ S e r u mN G A Ll e v e l sa ti n i t i a t i o no fR R Tw e r ei n d e -
pendently related to the severity of AKI and the extent
of systemic inflammation.
￿ T h er e s u l t sf r o mt h i ss t u d yi n d i c a t et h a ts e r u m
NGAL is an independent predictor of 28-day mortality
in ICU patients with dialysis-dependent AKI.
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